This is impactful because it creates an intersection between HR+ and triple-negative breast cancer, according to Neelam Patel, PharmD, BCOP, clinical pharmacy specialist at MD Anderson Cancer Center in Houston, Texas. Until recently, treatment for HER-2 low disease has been very limited to conventional cytotoxic therapies, which have performed very poorly. It's been a typically very difficult disease to treat.” 1 “Triple-negative disease is an unfortunate label in that it tells you the 3 things that the cancer is not about: It's lacking in 2 hormone receptors and it's lacking in HER2 by positivity definitions, but it tells you nothing about what's actually biologically driving that disease. there's an intersection with what we call triple-negative disease,” McArthur said. “HER2-low disease impacts mostly HR+ disease. With approximately 75% to 80% of breast cancers positive for hormone receptors in either the estrogen receptor and/or the progesterone receptor, this represents the vast majority of the patient population, explained McArthur. “The impact of a novel therapy that impacts 50% of our patient population is really huge.” 1įurther, HER2-low disease predominantly impacts patients with hormone receptor-positive (HR+) disease. ![]() So, 1 in 7 or 1 in 8 women are affected with breast cancer in their lifetime,” said McArthur, Komen Distinguished Chair in Clinical Breast Cancer Research and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center, as well as a clinical director of the Breast Cancer Program at Simmons Cancer Center in Dallas, Texas. ![]() ![]() “We have about 300,000 new breast cancer cases diagnosed in the United States every year and more than a million cases diagnosed worldwide every single year. 2 Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes. ADCs are complex targeted agents composed of a cytotoxic drug hanging on an antibody scaffold that can provide more directed and less toxic treatment for patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |